| Nota di contenuto |
Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- Part 1 -- Unraveling Ethnic Disparities in Triple-Negative Breast Cancer (TNBC): Exploring The Impact of Metabolic, Reproductive, Environmental, and Social Factors on the Disease Course in African-American (AA) Women Population -- INTRODUCTION -- HOW CAN WE APPROACH ETHNIC DISPARITIES IN TNBC SURVIVAL? - A ROADMAP OF POSSIBLE UNDERLYING BIOLOGIC AND NON-BIOLOGIC RISK FACTORS OR CAUSES OF TNBC IN AA VS. EA (OR NHW) WOMEN -- A SPOTLIGHT ON THE FAMILY HISTORY AND GENETIC MUTATIONS: THE IMPACT OF ETHNICITY ON MOLECULAR MAKE-UP IN TNBC -- SOCIOECONOMIC DISPARITIES IN BC - A LINK BETWEEN THE ECONOMIC DEPRIVATION AND DYSFUNCTIONAL HEALTHCARE PATH -- BEHAVIORAL AND CULTURAL FACTORS ACCOUNTING FOR BC DISPARITIES IN AA WOMEN -- THE UNDERESTIMATED ROLE OF INSUFFICIENT PHYSICAL ACTIVITY AS A RISK FACTOR IN BC DISPARITIES - REFLECTIONS FROM THE SELECTED CLINICAL STUDIES -- IMPACT OF INADEQUATE NUTRITION ON BC DISPARITIES -INSIGHTS FROM MAJOR CLINICAL STUDIES -- CONCLUSION -- REFERENCES -- A Closer Look at the Androgen Receptor (AR)-positive and AR-negative Metastatic Triple-Negative Breast Cancer: Can We Apply Novel Targeted Therapeutics? -- INTRODUCTION -- Various Molecular Subtypes of TNBC -- THE UNDETERMINED PROGNOSTIC VALUE OF ANDROGEN RECEPTOR (AR) IN WOMEN WITH TNBC -- THE INFLUENCE OF ANDROGEN RECEPTOR (AR) ON POTENTIAL THERAPEUTIC CHOICES IN PATIENTS WITH TNBC -- DIFFICULTIES WITH STANDARDIZATION OF ANDROGEN RECEPTOR (AR) TESTING -- TARGETED APPROACHES TO TNBC RESISTANT TO THERAPY: FOCUSING ON "WEAK POINTS" OF AGGRESSIVE CANCERS -- Immune Checkpoint Inhibitors (ICI) (Atezolizumab and Pembrolizumab) -- POLY-ADP-RIBOSE POLYMERASE (PARP) INHIBITORS (OLAPARIB AND TALAZOPARIB) -- Anti-Trop-2 Antibody-drug Conjugate (ADC) (Sacituzumab Govitecan-hziy).
SELECTED ACTIONABLE PHARMACOLOGIC TARGETS AND EMERGING THERAPIES ON THE HORIZON -- CONCLUSION -- REFERENCES -- Liquid Biopsy: Insights Into Monitoring Tumor Dynamics and Response to Therapy in Patients with Breast Cancer -- INTRODUCTION -- HOW LIQUID BIOPSY CAN BE USED IN MONITORING METASTATIC BC PROGRESSION AND TREATMENT? -- TRANSLATING A LEARNING EXPERIENCE FROM THE SOLAR-1 TRIAL INTO CLINICAL PRACTICE: THE APPROVAL OF ALPELISIB AND THERASCREEN -- AN IMPORTANCE OF CTDNA MUTATIONAL ANALYSIS IN THE MANAGEMENT OF PATIENTS WITH METASTATIC BC -- CIRCULATING TUMOR DNA ANALYSIS TO HELP DIRECT THERAPY IN ADVANCED BC (PLASMAMATCH): THE UNIQUE TOOL TO IDENTIFY SENSITIVITY -- AN IMPACT OF THE LIQUID BIOPSY ON THE PERSONALIZED TREATMENT OF WOMEN WITH METASTATIC BC -- Useful Ways of Predicting the Patients' Survival and BC Recurrence -- Can the Circulating Tumor Cell (CTC) Count be Used for a Selection of the First-line Therapy (CHT or ET) in Women with HR-positive, HER2-negative Metastatic BC? -- Can ctDNA Monitoring During the Neoadjuvant Chemotherapy (CHT) Course Reveal a Patient's Risk for Distant BC Metastases? -- Can Lack of ctDNA Clearance in Early Period of Neoadjuvant Chemotherapy (NAC) be a Predictor of Poor Response to Treatment? -- How to Predict the BC Metastatic Relapse Before the Clinical Recurrence? -- CONCLUSION -- REFERENCES -- Importance of Biomarker Conversions as "Road Signs" to Manage Women with Metastatic Breast Cancer: How To Use Them for Personalized Care of These Patients? -- INTRODUCTION -- COMMON CONVERSIONS OF BIOMARKER'S STATUS IN METASTATIC BREAST CANCER -- ALTERATIONS OF THE BIOMARKER'S STATUS IN METASTATIC BREAST CANCER AND THEIR POTENTIAL ROLE IN THE PROGNOSIS AND THERAPY -- COMMON BIOMARKERS OR THEIR COMBINATIONS MATCHED WITH TARGETED TREATMENTS FOR BREAST CANCER.
BIOMARKERS' SHIFTS IN METASTATIC BREAST CANCER AND THEIR REASSESSMENT: A POTENTIAL ROLE IN THE PROGNOSIS AND TREATMENT -- CONSIDERATIONS OF INTERTUMOR AND INTRATUMOR HETEROGENEITY: CHALLENGES AND OPPORTUNITIES -- Tumor Evolution and Its Connections with Changing of the Biomarker's Status in Metastatic Breast Cancer -- CONCLUSION -- REFERENCES -- Putting It All Together: Clinical Pearls of Recently Approved Therapies for Triple-Negative Breast Cancer -- INTRODUCTION -- A SPECIAL TASK OF PARP INHIBITORS: TARGETING ENZYMES THAT REPAIR DNA DAMAGE -- WHO CAN BENEFIT THE MOST FROM PARP INHIBITORS? - GOOD NEWS FROM THE OLYMPIAD AND THE EMBRACA TRIALS FOR WOMEN WITH METASTATIC BRCA-POSITIVE TNBC -- Shifting Gears to Immunotherapy: Who Can Be A Winner? -- The Role of Ventana and Dako Assay in PD-L1 Testing -- Sacituzumab Govitecan - An Antibody Drug Conjugate (ADC) Starting the "Optimistic Wave" of Therapy for Patients with Metastatic TNBC -- A Spotlight on HER2-low BC: Diagnostic Challenges to HER2 Status Interpretation -- The Remarkable Place of ADCs for Patients with Metastatic TNBC and HER2-low BC -- How to Put Immune Checkpoint Inhibitors and PARP Inhibitors Into Perspective? Considerations of Targeted Therapeutic Options and Their Sequence in Patients with TNBC Associated With the BRCA Mutation and PD-L1 Positivity -- CONCLUSION -- REFERENCES -- The Way Out From the Labyrinth of Anticancer Therapies for Patients with Breast Cancer: How Can We Improve Their Cardiac Safety and Quality of Life? -- INTRODUCTION -- FREQUENT SIDE EFFECTS OF ANTICANCER TREATMENTS AND THEIR PERCEPTION IN PATIENTS WITH BREAST CANCER -- A SPOTLIGHT ON TWO "FACES" OF PAIN SECONDARY TO ANTICANCER THERAPIES IN PATIENTS WITH BREAST CANCER: PERIPHERAL NEUROPATHY AND LYMPHEDEMA.
HOW CAN WE APPROACH DEPRESSION AND COGNITIVE IMPAIRMENT IN PATIENTS WITH BREAST CANCER FROM DIFFERENT PERSPECTIVES? -- HOW CAN WE ADDRESS THE MANAGEMENT OF MENOPAUSAL SYMPTOMS IN YOUNGER WOMEN UNDERGOING CHEMOTHERAPY FOR BREAST CANCER? -- HOW TO ASSESS CARDIOTOXICITY RELATED TO TREATMENTS FOR BREAST CANCER? -- MAY STANDARD PHARMACOTHERAPY FOR HEART FAILURE PROVIDE CARDIOPROTECTIVE EFFECTS FOR WOMEN WITH BREAST CANCER? -- HOW TO REDUCE CARDIOTOXICITY RELATED TO TREATMENTS FOR BREAST CANCER? FOCUS ON CARDIO-ONCOLOGY, REHABILITATION, AND INTEGRATIVE INTERVENTIONS -- FURTHER DIRECTIONS: EFFORTS TO DEVELOP THE "KNOWLEDGE NETWORK" FOR PERSONALIZED MEDICINE GOALS -- CONCLUSION -- REFERENCES -- Can We Find A Noninvasive Tool of Precision Medicine That Can Always Be Used For the Individualized Treatment of Women With Breast Cancer? -- INTRODUCTION -- The Goals and Tools of Precision Medicine -- AN EMERGING P4 MODEL: TRANSFORMATION FOR A NEW HEALTHCARE SYSTEM -- A Role of Personomics as A Tool to Fulfill the Unmet Healthcare Needs -- The Aliki Initiative: Teaching Personomics In The Academic Setting -- Unique Values of the Patient-centered, "Humanistic" Approach to Medical Management -- Current Possibilities of Personalized Medical Care for Women with Breast Cancer -- COMMON LIMITATIONS OF PERSONALIZED MEDICAL CARE FOR WOMEN WITH BREAST CANCER -- Selected Therapeutic Targets in Advanced or Metastatic TNBC -- CONCLUSION -- REFERENCES -- Part 2 -- Distress - Our "Internal Enemy": How to "Disarm" or Lessen its Negative Impact on the Psychophysical Condition of Women with Triple-Negative Breast Cancer? -- INTRODUCTION -- WHAT CAN PATIENTS WITH CANCER, CANCER CARE TEAMS, AND CAREGIVERS DO WHEN THE DISTRESS BECOMES VERY SERIOUS? -- Simple Tools to Help Measure Distress.
HOW TO TAKE AN ACTIVE ROLE IN PERSONAL MANAGEMENT OF THE CANCER-RELATED DISTRESS AND COOPERATE WITH THE CANCER CARE TEAM? - THE ART OF "DO'S" AND "DON'TS" -- HELPFUL OPTIONS TO MANAGE CANCER-RELATED DISTRESS AND ITS COMPLICATIONS -- CONCLUSION -- REFERENCES -- Teaching the Brain How to Counteract Distress: Practical Lessons About the Stress and Relaxation Responses for Women with Triple-Negative Breast Cancer -- INTRODUCTION -- OPPOSITE PHYSIOLOGIC ACTIONS OF TWO PARTS OF THE AUTONOMIC NERVOUS SYSTEM (ANS) - THE SYMPATHETIC NERVOUS SYSTEM (SNS) AND THE PARASYMPATHETIC NERVOUS SYSTEM (PNS) -- HOW THE PARASYMPATHETIC NERVOUS SYSTEM (PNS) ACTIVATION CAN BE APPLIED TO BENEFIT WOMEN WITH TNBC? -- COMBINING THE AWARENESS ABOUT AUTONOMIC NERVOUS SYSTEM (ANS) SIGNALS WITH INFORMAL APPLICATIONS OF COGNITIVE AND BEHAVIORAL INTERVENTIONS: HOW TO MAKE A POSITIVE TRANSFORMATION? -- ELICITING RELAXATION RESPONSE TO RESTORE A CALMING BALANCE OF THE MIND AND A HEALING POTENTIAL OF THE BODY -- HOW TO TEACH THE BRAIN TO REENGAGE IN THE REPAIR OF SOME STRESS-RELATED DAMAGES? - A THERAPEUTIC "MENU" TO CHOOSE FROM, FOR WOMEN WITH TNBC -- CONCLUSION -- REFERENCES -- An Intersectional Neuroscience Approach for Disadvantageous Populations: Meditation Practice as a Possible Support Option for Women with Breast Cancer? -- INTRODUCTION -- Intersectional Neuroscience (IN) - A Novel Research Model That Can Help Determine Mental States during Meditation in Diverse Populations of Participants -- EVALUATING MULTIVARIATE MAPS OF BODY AWARENESS (EMBODY) - THE INNOVATIVE TASK TO "DECIPHER" MENTAL STATES DURING THE BREATH-FOCUSED MEDITATION -- A POSSIBLE APPLICATION OF THE COMMUNITY-BASED PARTICIPATORY RESEARCH (CBPR) TO INTRODUCE INTERSECTIONAL METHODOLOGY TO BRIDGE THE GAP BETWEEN RESEARCH AND PRACTICE.
HOW THE DIFFERENT ATTENTIONAL STATES DURING THE BREATH-FOCUSED MEDITATION CAN BE MEASURED?.
|
Info
The Management of Metastatic Triple-Negative Breast Cancer
